|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
neuraminidase inhibitor
|
|
gptkbp:appointed_by
|
inhalation
|
|
gptkbp:approves
|
gptkb:1999
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Relenza
|
|
gptkbp:clinical_trial
|
Phase III
prophylaxis of influenza
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
gptkb:asthma
COPD
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dissolved
|
soluble in water
|
|
gptkbp:distribution
|
widely used in many countries
|
|
gptkbp:dosage_form
|
inhalation powder
|
|
gptkbp:formulation
|
powder for inhalation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zanamivir
|
|
gptkbp:ingredients
|
C12 H20 N4 O7
|
|
gptkbp:interacts_with
|
gptkb:amantadine
gptkb:oseltamivir
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
effective against H1 N1
effective against H3 N2
effective against influenza B
reduces duration of influenza symptoms
|
|
gptkbp:is_used_for
|
treatment of influenza
|
|
gptkbp:manager
|
oral inhalation
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:provides_information_on
|
CDC recommendations
WHO guidelines
|
|
gptkbp:research_areas
|
antiviral therapy
respiratory viruses
influenza treatment
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
allergic reactions
cough
diarrhea
bronchospasm
throat irritation
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:targets
|
gptkb:virus
|
|
gptkbp:type_of
|
139110-80-8
|
|
gptkbp:weight
|
292.31 g/mol
|
|
gptkbp:bfsParent
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
4
|